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TITLE: Adenovirus-associated pneumonia in South African children: presentation, clinical course and 
outcome. 
Authors: Zakira Mukuddem-Sablay; Marco Zampoli 
Affiliations: Department of Paediatrics and Child Health, University of Cape Town 
Background: Pneumonia is an important cause of morbidity and mortality in children. Viruses have 
emerged as important aetiological agents in childhood pneumonia. The aim of this study was to 
document the clinical presentation, severity and outcome of adenoviral-associated pneumonia (AVP) in 
children and identify risk factors associated with poor outcome. 
Methods: A retrospective study of laboratory-confirmed AVP cases was conducted between 1 January 
and 31 December 2011. The medical records of adenovirus PCR positive respiratory tract samples 
identified through the National Health Laboratory Service (NHLS) database were retrieved. 
Demographic, clinical and outcomes data of children with AVP was extracted and analysed. Outcome 
measures were death and development of chronic lung disease (CLD). 
Results: 1910 respiratory samples were submitted to the NHLS from which 206/1910 (11%) AVP cases 
were identified. The median age was 12 months (IQR 6-24), 70 (34%) children were malnourished and 
14 (7%) HIV-infected. Fever was the commonest presenting symptom occurring in 159 (77%) of cases. 
Seventy six (37%) required intensive care unit (ICU) admission. There was a high prevalence of co-
morbid conditions with 98 (47%) having at least one; cardiac disease was the most common (48 (23%). 
Twenty nine (14%} developed CLD which was associated with hypoxia at presentation (26/29, 90%, p = 
0.01) and admission to ICU (18/29, 62%, p < 0.01). Eighteen (9%) children died. Admission to ICU (OR 
8.3, 95% Cl 2.3- 29.0) and blood stream infection (OR 11.2; 95% Cl 2.3-54.1) were independent risk 
factors for mortality. 
Conclusion: Adenoviral-associated pneumonia is an important cause of pneumonia and CLD in young 
children in South Africa. Admission to ICU and blood stream infection were associated with poor 
outcome. 
Funding: department of Paediatrics and Child Health, UCT 
Conflicts of interest: none declared 
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Abbreviations: 
AVP Adenoviral Pneumonia 
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Introduction and literature Review 
Worldwide, paediatric respiratory tract infections remain a common and significant source of morbidity 
and mortality. This is of particular importance in developing countries where pneumonia remains an 
important cause of death in children under the age of 5 years.111The WHO estimates 450 million cases of 
pneumonia are recorded annually with the most vulnerable groups being the under-fives and 
over75's.[2] Childhood pneumonia and diarrhoeal disease accounted for about 2 million deaths in 2011, 
with 81% of deaths due to pneumonia occurring in the first two years of life.[3] This remains concerning 
as most pneumonia deaths are preventable. Whilst paediatric pneumonia is a global problem, significant 
strides have been made in the developed world toward reducing both pneumonia incidence and 
pneumonia related mortality. Reduction in the under-5 mortality rate has dropped from 90 per 1000 live 
births in 1990 to 48 per 1000 in 2012. Despite this impressive statistic, 6,6million children under the age 
of five are still dying annually, with pneumonia the leading cause of death, accounting for approximately 
1, 3 million childhood deaths per annum. [4] At this rate the Millennium Development Goal number 
4(MDG4) is unlikely to be met by 2015, which aimed for a 2/3 reduction in under-5 mortality frorr. the 
1990 levels. Unless there is a dramatic change in policy, practice and prevention measures this target is 
only likely to be reached by 2028. African countries continue to lag behind significantly. Africa has one of 
the highest incidence rates of severe childhood pneumonia, accounting for almost half of all global cases 
of pneumonia. [s] In 2011, an estimated 120 million episodes of childhood pneumonia were reported 
globally. Of these, 14 million progressed to severe disease, with 1, 3 million deaths. Africa and Southeast 
Asia accounted for 69% of the global burden of severe cases. [4]1n 2012, Nair et.al analysed data from 89 
published 3nd unpublished studies on acute lower respiratory infections, noting that almost 15 million 
admissions occurred worldwide in 2010. Of these, 96% were in developing countries. [6] 
Evidence points to the fact that children in low and middle income countries are particularly at risk. 
Factors like poor nutrition, micronutrient deficiency, HIV infection, overcrowding and poor socio-
economic circumstances, prematurity, exposure to smoke and other environmental pollutants all 
contribute to increased severity of disease. In Sub-Saharan Africa, HIV is of particular importance as this 
population of children have higher mortality, with increased severity of infections as well as increased 
risk of opportunistic infections. Early implementation of antiretroviral therapy in addition to 
cotrimoxazole prophylaxis can reduce the burden of both pneumonia and severe disease in this at-risk 
group. rs]ln 2013, the WHO launched the Global action Plan for the Prevention and Control of 
Pneumonia and Diarrhoea (GAPPD), highlighting common strategies for prevention and treatment of 
these illnesses, as well as pneumonia-specific strategies. 
Pneumonia aetiology remains a challenge in the paediatric population, as bacteraemic sepsis in children 
is relatively uncommon and nasopharyngeal colonisation by pathogenic bacteria limits the use of 
respiratory samples for diagnosing bacterial pneumonia. [7] Gilani et.al reviewed 10 years of literature 
and pneumonia aetiology studies from 2000-2010 and reported that Streptococcus Pneumoniae is 
implicated in 18% of severe pneumonia cases and 33% of deaths. This is followed by Haemophilus 
influenzae type B, which accounts for 4% of severe episodes and 16% of deaths. [4] These are all vaccine-
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prevP.ntable causes of significant childhood morbidity and mortality. Pneumonia preventative measures 
have been bolstered by the introduction of conjugate vaccines against H.influenzae type B (Hib) and 
against S. Pneumoniae (PCV). In 2013, Bhutta et.al reviewed interventions to address deaths from 
childhood pneumonia and diarrhoea equitably and reported that the introduction of the Hib conjugated 
vaccine in low and middle income countries was associated with an 18% reduction in radiologically 
confirmed pneumonia, a 6% reduction in severe pneumonia and a 7% reduction in pneumonia-
associated mortality.[s] By 2011, approximately 90% of low-income countries had introduced HIB into 
their immunisation programmes through support from Global alliance For Vaccines and Immunisation 
(GAVI). Furthermore they reported data from six studies in low and middle income countries which 
estimated a 29% reduction in radiologically confirmed pneumonia, 11% reduction in severe pneumonia 
and an 18,5% reduction in pneumonia-specific mortality with the introduction of PCV.[7J The effect of 
widespread immunisation has also led to a dramatic decline in pneumonia-related hospitalisation rates 
in adults, especially the elderly due to herd immunity as well as reduced transmission of pneumonia-
specific serotypes in the United States. [7].PCV vaccination has also led to a reduction in hospitalisation 
for viral-associated pneumonia. Shabir Madhi's paper in 2004 revealed a 32% lower hospitalisation rate 
for viral associated pneumonia episodes in vaccinated children. [z]ln the United States, a 41-50% 
reduction in influenza-virus attributable pneumonia hospitalisation is estimated for every 10% 
increment in childhood PCV immunisation.[?] Despite this, PCV introduction into national immunisation 
programmes is still suboptimal, with Wang et.al reporting in 2013 that only 31% of the world's birth 
cohort currently having access to PCV.[s] Only 36% of countries with the highest mortality and 37% of 
countries in which more than 10% of deaths were pneumonia-related, had introduced PCV by 2012. 
Less than 50% of countries eligible for support from the Global alliance for Vaccines and 
lmmunisation(GAVI) had introduced PCV, with only 19 African countries introducing PCV into their 
national childhood immunisation programmes. [s]. 
Whilst global access to effective immunisation is still not 100%, improved immunisation against the main 
bacterial pathogens have resulted in respiratory viruses emerging as important aetiologic agents in 
childhood pneumonia. In the paediatric population in developed countries, respiratory viruses are the 
commonest cause of pneumonia. [3].Respiratory viruses were first discovered between 1933 and 1965, 
with the identification of the influenza virus, enterovirus, adenovirus, respiratory syncytial virus, 
rhinovirus, parainfluenza virus and coronaviruses by viral culture. In the early 2000's several new viruses 
were identified, and with the advent of molecular testing, the role of viruses in the aetiology of 
pneumonia has become clearer. [9] The incidence of viral pneumonia had hitherto been largely 
underestimated. [10] A majority of viral-associated lower respiratory tract infections are caused by 
Respiratory Syncytial virus (RSV), Human Metapneumovirus, Influenza A and B, adenovirus, Severe acute 
Resp;ratory Syndrome (SARS), Coronavirus and Bocavirus. [11] Adenovirus infections account for 5-15% 
of upper respiratory infections and 5% of childhood pneumonia. [11, 12].The discovery in the last decade 
of newer viruses like Human Metapneumovirus, Coronavirus, NL63 and HKU1, Human Bocavirus, new 
enterovirus, Polyomavirus, Parechovirus, SARS and H1N1 influenza virus have highlighted the fact that 
children remain a vulnerable population exposed to multiple viruses with similar seasonal patterns. [13] 
Whilst the role of RSV in childhood pneumonia is well established, the role of other viruses is less clear. 
Dual viral infections are common with a third of children having evidence of viral-bacterial co-infection. 
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[2] This is reflected in the findings by Niederman et.al who suggest that viruses account for up to 80% of 
infections in young children, with RSV and Rhinovirus being most commonly isolated. [14] With the 
emergence of severe acute respiratory syndrome (SARS), Avian Influenza A (HSN1) virus and the 2009 
H1N1 influenza pandemic, the role of respiratory viruses as a cause of severe pneumonia was again 
highlighted. 121 A Ghanaian study published in 2012 demonstrated the importance of respiratory viruses 
in childhood pneumonia comparable to worldwide trends [1s]. In South Africa, studies confirmed an 
increased burden of viral-associated respiratory tract infections in HIV-infected children. [14]. 
Furthermore, these children were shown to have increased severity of viral infections with higher 
morbidity and mortality. [14] More recently, Morrow et.al investigated the prevalence and outcome of 
patients admitted to a paediatric intensive care unit with viral respiratory tract infections in Cape Town. 
Their study showed that viral respiratory infections were common in their setting and a significant cause 
of morbidity and mortality. Rhinovirus incidence was highest, followed by RSV and adenovirus. Whilst 
RSV and Rhinovirus displayed a seasonal pattern, adenovirus did not and was present throughout the 
study period. [16] Comorbid factors like HIV exposure, HIV infection and congenital cardiac disease were 
significantly associated with poorer outcome. [16] 
Human adenoviruses are non-enveloped double-stranded DNA viruses which were first isolated from 
adenoidal cells in 1953 as part of a project searching for the virus responsible for the common cold. The 
57 recognised serotypes of Human Adenoviruses are divided into subgroups A to G. Tropism was found 
to exist amongst subgroups, with subgroup A and F typically causing GIT infection, subgroups B,C and E 
showing predilection for the respiratory tract and subgroup D associated with epidemic 
keratoconjunctivitis. Subspecies B includes serotypes 3, 7 and 21 which are associated with lower 
respiratory infections. [171 Adenovirus is typically transmitted from person to person by respiratory 
droplets and less commonly by the conjunctival and faecal-oral route. The incubation period is relatively 
short, ranging between 2 and 14 days. In normal hosts, illnesses usually last about 1 week, but 
asymptomatic shedding of virus can occur for months or years. Infections are commoner in winter and 
spring but may occur throughout the year. It is uncommon in the early neonatal period, suggesting that 
maternal antibodies confer protection. Neutralising antibodies develop in early childhood after 
symptomatic and asymptomatic infection which occur with equal frequency. By age 5, up to 75% of 
children have serologic evidence of adenovirus exposure. [17]These antibodies are thought to confer 
lifelong immunity against that particular serotype. [11] 
The prevalence of adenoviral associated pneumonia is fairly low (range 2-12%) but it remains an 
important infection to identify because of its ability to cause severe and fatal necrotising pneumonia 
[1s]. Despite this seemingly low incidence, adenoviruses may result in severe disease with resultant 
morbidity and mortality especially in high-risk patients. Serotypes 3, 7, 7a and 21 are the commonest 
cause of lower respiratory disease.[19] These serotypes are associated with severe disease as well as 
pulmonary sequelae such as bronchiectasis, bronchiolitis obliterans, (BO), unilateral hyperlucent lung 
and persistent abnormal pulmonary function.[n] 
In severe adenoviral pneumonia there is destruction of the bronchi and bronchioles with necrosis 
spreading to the adjacent parenchyma. Resolution of the acute illness results in the development of BO 
with chronic sequelae. [20] Bronchiolitis obliterans is a rare form of chronic obstructive lung disease that 
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follows a severe insult to the lower respiratory tract resulting in fibrosis of the small airways. Severe 
adenovirus pneumonia is known to bronchiolitis obliterans. [21]ln their systematic review on long term 
sequelae from childhood pneumonia in 2012, Edmund et.al reviewed published papers from 1970 to 
2011 to determine the risks of long term sequelae from childhood pneumonia in children under 5 years 
of age. Standard global burden of disease categories (restrictive lung disease, obstructive lung disease, 
bronchiectasis) were labelled as "major sequelae" whilst chronic bronchitis, asthma, other abnormal 
pulmonary function were labelled as "minor sequelae". Their review showed that hospitalised children 
had a 13, 6% risk of at least one major sequelae compared to non-hospitalised children where the risk 
was only 5, 5%. They also reported adenovirus pneumonia to be associated with the highest sequelae 
risk (54, 8%). [1s] 
The earliest review article on adenovirus pneumonia published in 1959 from Japan, described three 
cases of severe infantile pneumonia. [21]ln 1973, an outbreak of adenovirus Type 7 was reported in 
Montreal, Canada. 13 infants and children with proven adenovirus type 7 were described; 4 were 
ventilated, 3 died and 1 developed chronic lung disease.[21]ln Feb 1997 Canadian researchers published 
data on a lOyear follow up study of 19 children who had been treated for pneumonia; 14 of them had 
developed severe pneumonia and had bronchiectatic changes at follow up. In all 14 cases adenovirus 
type 3 had been identified. This was one of the earliest studies suggesting a link between adenovirus 
infection and chronic lung disease. [22] 
Hyperlucent lung was first described by Sawyer and James in 1953, followed by Mcleod in 1954. 
[23]Typically diagnosed radiologically as a unilateral lung appearing less dense on CXR. In addition, the 
pulmonary vessels are smaller than normal and bronchographic pictures suggest widespread obstruction 
of small bronchi with air trapping. This phenomenon was described by Canadian researchers in 1983 and 
again, adenovirus type7 was implicated in several cases. [23].A further study in 1984 had followed a 
cohort of 20 children admitted with confirmed adenovirus type 7 pneumonia. They were compared to 
20 controls with adenovirus Type 7 upper respiratory tract infections: 65% of the pneumon;a group had 
evidence of airway obstruction compared to 10% of the control group. Young age at time of infection 
was identified as an independent risk factor for long-term pulmonary function abnormality. [24] Most of 
the recent work on adenoviral infections, including complications comes from South America, 
particularly Argentina where adenoviruses are the second most prevalent cause of acute lower 
respiratory infection of viral origin in children under age of four, surpassed only by RSV.[n] One of the 
largest studies on post infectious BO came from Argentina in 2009, where Patricia Murtagh et.al did a 
retrospective observational study on 415 children hospitalised with adenoviral pneumonia over a 7 year 
period: 49% children recovered fully, 36% developed sequelae and 15% died. Independent risk factors 
for developing bronchiolitis obliterans were identified and included prolonged hospitalisation (more 
than 30 days), multifocal pneumonia and hypercapnia. Independent risk factors for death in the acute 
phase of the illness were mechanical ventilation, multifocal pneumonia, hypercapnia, coagulation 
disorders and co-infection with measles. [11] These results echoed the findings by Colom et.al in 2006 
whose study also showed that early aggressive disease needing ventilatory assistance with prolonged 
hospitalisation was associated with subsequent development of bronchiolitis obliterans. [2s] Castro 
Rodrigues et.al prospectively assessed 45 hospitalised children with adenovirus pneumonia over a 5 yr 
12 
period in an attempt to identify factors that potentially contribute to the development of Bronchiolitis 
Obliterans. At the end of their study period, 38 surviving patients were divided into 2 groups: those with 
CT evidence of BO and those without. The group who had CT evidence of BO had primary infection 
before age of 2 years. Those who developed BO had a more severe initial illness, requiring ICU, 
supplemental oxygen therapy, ventilatory assistance and steroids. [26] Finally, in 2009, Celom et.al 
devised a clinical prediction rule to diagnose post infectious BO in children. They developed and 
validated a clinical prediction rule (BO score) using multiple objectively measured parameters that were 
readily available; 125 patients were included in this study. The BO score was derived by assigning points 
to the following variables. Typical clinical history=4 points, adenoviral infection confirmed =3 points, CT 
showing mosaic lung perfusion pattern=4 points. A score of 7 or more predicted BO outcome with 100% 
specificity and 67% sensitivity. They concluded that the BO score is simple to use, and that a score of 7 
or more predicts post infectious BO with high accuracy. [21] 
The epidemiology, clinical presentation and complications of adenovirus -associated pneur1onia in 
South African children is unknown. Like South American countries, local clinical experience would 
suggest that the morbidity and long-term sequelae of adenovirus-associated pneumonia are significant. 
Furthermore, the role of HIV infection on the outcome of adenovirus-associated pneumonia is unknown. 
Multiplex PCR testing (which includes multiple adenovirus serotypes) was introduced in 2009 as the 
diagnostic test on all routine respiratory tract samples from Red Cross War Memorial Children's Hospital 
(RCWMCH). 
The purpose of this study is to report the presentation, clinical course and outcome of laboratory-
confirmed adenovirus associated pneumonia at RCWMCH. 
Summary of literature review methods 
This literature review aims to review the epidemiology of childhood pneumonia, summarise the 
aetiology of pneumonia, review the role of viruses in paediatric pneumonia in the developed as well as 
the developing world, review the epidemiology, prevalence , clinical features and outcome of 
adenovirus pneumonia in the literature. 
Searchstr~ 
The Literature review search was conducted on Pubmed (www.ncbi.nlm.nih.gov/pubmed) and Medline 
(www.ncbi.nlm.nih.gov) using the following search strings. PNEUMONIA and CHILDHOOD and 
AETIOLOGY or AETIOLOGY and AFRICA AND DEVELOPING COUNTRIES. 
A second search was done using ADENOVIRUS and PNEUMONIA and CHILDREN and COMPLICATIONS 
The inclusion criteria were: all English language articles, articles focusing on childhood pneumonia, 
studies looking specifically at Adenoviral infections in children. Articles reviewing the role of viruses 
were included as well. Articles specific to Africa were included. Abstracts derived from the above search 
were also reviewed. Those which met inclusion criteria were reviewed in full text. Those articles were 
further filtered and references cited within the articles were searched and reviewed. Relevant articles 
identified by the supervisor were also included and cross-referenced. 
Results 
The initial search was conducted in May 2012 prior to writing the research proposal. This process was 
repeated in October 2014, prior to writing the final literature review. 
The search strings (PNEUMONIA and CHILDHOOD and AETIOLOGY and AFRICA and DEVELOPING 
COUNTRIES plus ADENOVIRUS and PNEUMONIA and CHILDREN and COMPLICATIONS) yielded 214 
articles. The inclusion and exclusion criteria were applied and 51 articles were reviewed in full text. 51 
articles were included in this literature review, including studies from developed and developing 
countries. Most articles were recent, with publication between 2000 and 2014. Three relevant articles 
from 1959-1989 were included. All articles were relative to the paediatric population. 
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EPIDEMIOLOGY: 5 updated articles published between 2012 and 2014 were reviewed. These articles 
served to give the reader a clear understanding of the enormity of the pneumonia burden worldwide. 
They also highlight the contribution of pneumonia to under5 morbidity and mortality and how 
respiratory disease impacts on child health. 3 articles stressed the challenges pneumonia continues to 
pose in Africa, with Professor Zar's article in the Thorax journal of 2013 discussing progress that has 
been made in addition to the continued challenges we face in Africa. [1, s,7]. One systematic review 
published in 2013 reviewed the global burden of hospital admissions for severe acute lowe1· respiratory 
infections in children.[G] 
PNEUMONIA AETIOLOGY: 21 articles pertaining to pneumonia aetiology were reviewed and analysed. 
The role of well -known bacteria, Streptococcus Pneumoniae and Haemophilus influenzae were 
studied.[s.7] Several articles reviewed the enormous strides made with improved immunisation 
schedules globally although many African countries still lag behind. [sJ With the advancement of 
immunisation strategies, the role of viruses in childhood pneumonia aetiology was reviewed. [2a]. Much 
has been studied and reported in the literature with regards to the role that viruses play in respiratory 
infections in the developed world, but a review of the literature revealed a scarcity of such studies in 
Africa. A total of 3 studies were identified in North Africa, with a few studies from South Africa, several 
slanted toward the effect of co-infection with HIV. [2,14,15,29,30,31,32] A review on the history of viral 
infections, their discovery and role in childhood pneumonia was completed. Studies allude to the fact 
that until multiplex testing for respiratory viruses became readily available, the contribution of viruses 
to pneumonia aetiology was largely underestimated. [9] The recent SARS and H1N1 outbreak again 
highlighted the important role viruses play in childhood pneumonia. The role of multiple viral infections 
as well as bacterial co-infection in childhood pneumonia was explored, revealing high incidence of both 
in the paediatric population. HIV exposure and infection were both identified as risk factors for severe 
pneumonia, with the added burden of opportunistic infections in this susceptible group. A study at Red 
Cross War Memorial Children's Hospital showed significant morbidity and mortality in their Paediatric 
ICU amongst children admitted with viral LRTI's. HIV, malnutrition and congenital cardiac disease were 
associated with poorer outcome. [16] 
Adenovirus-associated pneumonia and its sequelae: Adenoviruses were reviewed. A Primary Pubmed 
search using ADENOVIRUS and PNEUMONIA and CHILDHOOD revealed 60 articles, 20 of which were 
foreign language articles and therefore excluded. The remaining articles were scanned and 14 articles 
included in the literature review. These articles looked at the history of adenoviral infections, 
epidemiology, and the contribution of adenoviruses to childhood morbidity and mortality. 
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ABSTRACT 
TITLE: Adenovirus-associated pneumonia in South African children: presentation, clinical course and 
outcome. 
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Background: Pneumonia is an important cause of morbidity and mortality in children. Viruses have 
emerged as important a etiological agents in childhood pneumonia. The aim of this study was to 
document the clinical presentation, severity and outcome of adenoviral-associated pneumonia (AVP) in 
children and identify risk factors associated with poor outcome. 
Methods: A retrospective study of laboratory-confirmed AVP cases was conducted between 1 January 
and 31 December 2011. The medical records of adenovirus PCR positive respiratory tract samples 
identified through the National Health Laboratory Service (NHLS) database were retrieved. 
Demographic, clinical and outcomes data of children with AVP were extracted and analysed. Outcome 
measures were death and development of chronic lung disease (CLD). 
Results: 1910 respiratory samples were submitted to the NHLS from which 206/1910 (11%) AVP cases 
were identified. The median age was 12 months (IQR 6-24), 70 (34%) children were malnourished and 
14 (7%) HIV-infected. Fever was the commonest presenting symptom occurring in 159 (77%) of cases. 
Seventy six (37%) required intensive care unit (ICU) admission. There was a high prevalence of co-
morbid conditions with 98 (47%) having at least one; cardiac disease was the most common {48 (23%). 
Twenty nine (14%) developed CLD which was associated with hypoxia at presentation (26/29, 90%, p = 
0.01) and admission to ICU (18/29, 62%, p < 0.01). Eighteen (9%) children died. Admission to ICU (OR 
8.3, 95% Cl 2.3- 29.0) and blood stream infection (OR 11.2; 95% Cl 2.3-54.1) were independent risk 
factors for mortality. 
Conclusion: Adenoviral-associated pneumonia is an important cause of pneumonia and CLD in young 





Respiratory tract infections remain a common and significant source of morbidity and mortality in 
children worldwide. This is of particular importance in developing countries where pneumonia is an 
important cause of death in children under five years of age.[lJ Whilst global access to effective 
immunisation against common bacterial pathogens slowly improves, resp;ratory viruses have emerged 
as important aetiologic agents in childhood pneumonia. This holds particularly true in developed 
countries, where respiratory viruses are the commonest cause of childhood pneumonia. [1] Most viral 
associated lower respiratory tract infections are caused by respiratory syncytial virus (RSV), Human 
metapneumovirus,influenza A and B, adenovirus, Severe Acute Respiratory Syndrome (SARS), 
coronavirus and bocavirus. [2] Data from an American study looking at community acquired peumonia 
requiring hospitalisation between 2010 and 2012 revealed that RSV, adenovirus and metapneumovirus 
are commoner in children under age of 5 than amongst older children. Adenovirus prevalence was 15% 
in the under -5 group compared to 3% in older children. [3] 
Adenovirus infections account for 5-15% of upper respiratory infections and 5% of childhood lower 
respiratory tract infections (LRTI's). [4, s]The ability of adenoviruses to cause severe and fat<d necrotising 
pneumonia is well known and may result in significant morbidity and mortality especially in high risk 
patients. Serotypes 3, 7, 7a and 21 are the commonest cause of lower respiratory disease. [s] Their 
association with pulmonary sequelae such as bronchiectasis, BO, unilateral hyperlucent lung and 
persistent abnormal pulmonary function have been well described. [4]1n a meta-analysis, adenovirus 
pneumonia in childhood was reported to be associated with the highest sequelae risk for chronic lung 
disease in adulthood. [6] 
Whilst the role of RSV in childhood pneumonia is well established, the role of other viruses is less clear. 
Results from a Kenyan study from 2010 which aimed to determine the viral aetiology of severe 
pneumonia amongst infants and children revealed RSV to be most prevalent and associated with severe 
disease. Adenovirus and metapneumovirus accounted for only 3.8% of cases. [7]Dual viral infections are 
common with a third of children having evidence of viral-bacterial co infection. [s]ln South Africa, 
studies have confirmed an increased burden of viral associated respiratory tract infections in human 
immunodeficiency virus (HIV) infected children and children admitted to intensive care (ICU) with severe 
pneumonia.[9. 10.111 Morrow et al compared spectrum, course, seasonality and outcome of children 
with virus-associated respiratory symptoms (VARS) admitted to two paediatric ICUs in the United 
Kingdom (UK) and South Africa (SA). They found that the outcome of children with VARS was worse in 
SA compared with the UK. Adenovirus was more common in SA and also an independent risk factor 
associated with mortality. 111] 
The epidemiology, clinical presentation and complications of adenovirus-associated pneumonia (AVP) in 
South African children is unknown. Furthermore, the role of HIV infection and malnutrition on the 
outcome of AVP is unknown. This study aimed to document the presentation, clinical course and 
outcome of AVP at a tertiary paediatric referral hospital in South Africa. 
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METHODS 
Study design and patient selection 
A retrospective descriptive study was conducted at Red Cross War Memorial Children's Hospital 
(RCWMCH), a tertiary paediatric hospital in Cape Town, South Africa. Children 0-13 years of age 
admitted from 1" January 2011 to 31 December 2011 with laboratory- confirmed AVP were enrolled. 
For the purposes of this study, AVP was defined as pneumonia (cough, tachypnoea with or without chest 
indrawing) and isolation of adenovirus from any respiratory tract samples which included tracheal 
aspirates(TA's), bronchoalveolar lavage (BAL), induced sputums (IS), nose swabs or nasopharyngeal 
aspirates (NPA's). The National Health Laboratory Service (NHLS) database was searched to extract all 
PCR adenovirus positive respiratory samples collected in children admitted to RCWMCH within the study 
period. Respiratory viruses were identified using SeeplexRV7 Detection assay (Seegene, Seoul, Korea) 
which includes influenza A, influenza B, human metapneumovirus, respiratory syncytial virus, 
rhinovirus A, parainfluenza virus and adenovirus. 
All laboratory identified adenovirus positive cases of children admitted to RCWMCH where medical 
records were available were included in the study. 
Clinical and laboratory data 
The medical records of identified patients were retrieved and relevant data recorded on a data capture 
form. Clinical and demographic information at the time of hospital admission or acquisition of hospital 
acquired infection was collected. The presence of fever more than 38 degree Celsius for more than 48 
hours, diarrhoea, conjunctivitis and skin rash was recorded. Adenovirus-associated pneumonia cases 
were classified into community acquired or hospital acquired pneumonia. Community acquired AVP was 
defined as AVP confirmed within 48 hours of hospital admission. Hospital acquired AVP was defined as 
AVP acquired more than 48hours after hospital admission. 
The HIV status of patients was classified as: HIV exposed but uninfected, HIV exposed and infected or 
HIV unexposed. In the HIV -infected group, CD4 count and percentage, HIV viral load and antiretroviral 
treatment details were recorded. The nutritional status of each child was determined by calculating the 
World Health Organisation (WHO) weight-for-age z-score (WAZ score) using igrowup macro for STAT A 
(WHO Anthro version 3.2.2).Malnutrition was defined as a z-score of less than -2. The presence of an 
underlying medical condition was recorded and categorised as cardiac, respiratory, renal, neurologic, 
immune-suppression, prematurity or other. 
Routine laboratory investigations that were recorded were the total white cell count, haemoglobin, C-
reactive protein (CRP) and pro-calcitonin (PCT) at the time of hospital admission. The presence of 
significant laboratory-confirmed co-infections were documented and recorded as: other respiratory 
viruses, bloodstream infections (positive blood culture) and tuberculosis (positive culture of 
M. Tuberculosis from a site). 
Pneumonia severity was established according to the presence or absence of hypoxia at admission, 
(oxygen saturation<90% in room air), need for ICU admission and need for ventilatory support. The 
ventilation modality and total duration of ventilation and ICU stay was recorded. 
Outcome Measures 
Two outcome measures were examined. Development of chronic lung disease (CLD) and in-hospital 
mortality. Chronic lung disease was defined as the ongoing need for supplemental oxygen beyond 30 
days of hospital admission. 
Data Analysis 
23 
Data was collected and entered into an EpiData (Entry version2.0, Denmark) programme. Thereafter 
statistical analysis was done using SPSS programme (version 12). Data was tested for norm<Jiity using 
Shapiro-Wilks W-test. Data was not normally distributed and therefore presented as medians 
(interquartile ranges). Univariate analysis were conducted using Yates-corrected chi-square tests where 
cell values were <10. Logistic regression analysis was conducted for risk factors for death outcome using 
variables with p value< 0.05. 
RESULTS 
Between January 1" 2011 and December 31" 2011 a total of 1910 respiratory samples were submitted 
to the NHLS from RCWMCH for viral PCR testing. Of this group 206/1910 (11%) samples tested were 
positive for adenovirus, with 56/206 (27%) of these testing positive for additional respiratory viruses. A 
total of 206 patients with AVP were identified and included in this study. 
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS (tablel) 
The median age was 12 months (IQR 6- 24) with a slight male predominance. Thirty four percent 
(70/206) of the study population was malnourished and 72% (148/206) were community acquired 
infections. Fever was the commonest presenting complaint, documented in 77% of cases. There was a 
high prevalence of underlying medical conditions with 47% of the study sample having at least one 
underlying medical condition, 16% having more than one and 37% having none. There were fourteen 
HIV infected children in the study sample. Twelve out of the fourteen children were either on 
antiretrovirals at the time of their infection or initiated on treatment during this admission. 
The mean WCC on admission was 15 x109/L (SD8) and mean Hb of 11g/dL (SD2). The mean CRP and PCT 
were 20mg/L (IQR 5-53 n=145) and 2,5ug/L (IQR 1-12, n=10) respectively. 
PNEUMONIA SEVERITY: Hypoxia was a significant finding with 146(71%) children hypoxic on admission. 
76(37%) needed ICU admission for respiratory support, of whom 54/76(71%) were mechanically 
ventilated. 31/76 (41%) needed CPPV (continuous positive pressure ventilation) and 13/76 (17%) 
needed HFOV (high frequency oscillatory ventilation). The median stay in ICU was 9 days (IQR 4-17). The 
median length of hospital stay was 10 days (IQR 3- 21). 
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OUTCOM~S 
Chronic lung disease: 29 (14%) children developed CLD). Hypoxia (p=0,016) and admission to ICU 
(p=0,002)was significantly associated with the development of CLD. Compared to children without CLD, 
children with CLD had a longer median ICU stay of 9 days vs 5 days (p=0,06) and a longer median 
hospital stay of 41 days vs 9 days (p<O,OOl). 
In-hospital mortality: (table 2) Eighteen (9%) children died. 10/18(56%) of the deaths were adenovirus 
related and 8/18 (46%) were unrelated. Most children made a full recovery 168/206(82%) and were 
discharged with no sequelae. Hypoxia (p=O, 02) and ICU admission (p=O, 01) were associated with in-
hospital mortality on univariate analysis (table 2). Furthermore, underlying cardiac disease (p=O, 02)and 
blood stream infection (p=0,001) were additional factors associated with mortality. logistic regression 
analysis revealed that ICU admission (OR 8.3, 95% Cl 2.3- 29.0) and blood stream infection (OR 11.2; OR 
2.3-54.1) were independently associated with mortality; underlying cardiac disease trended towards 
significant association with mortality (OR 2.88, 95% Cl 0.98-8.5). 
DISCUSSION 
This is the first study undertaken looking at adenoviral respiratory infections in children specifically in a 
South African context. Much of the literature on this subject comes from South America and Asia where 
adenoviral infections and longterm sequelae thereof are commonly described. [•. 6,12,13,14,1s]ln this 
study, adenovirus was isolated in 11% of all respiratory tract samples that were tested thus highlighting 
the contribution of adenovirus in pneumonia aetiology in our setting. Furthermore, this study confirms 
previous reports of AVP causing severe pneumonia and significant morbidity in children as supported by 
our data documenting 37% of patients needing ICU admission and 14% developing chronic lung disease. 
Outcome was associated with pneumonia severity, ICU admission and bloodstream infections. 
Adenoviral viraemia may be associated with prolonged high fever as was observed in our study. [s. 16]. It 
is thought that 20% of all cases of paediatric conjunctivitis is due to adenovirus with seasonal 
predilection for autumn and winter. [11] Conjunctivitis in our study was less common than expected and 
can likely be explained by lower prevalence of adenovirus serotypes which cause conjunctivitis in our 
population. 
An underlying medical condition and malnutrition was found in almost half and one third of patients 
respectively. Prematurity and congenital cardiac disease were the most common underlying conditions 
which highlights the vulnerability of these conditions to severe adenovirus-associated pneumonia. 
Underlying cardiac disease tended towards a significant risk factor associated with death. Adenovirus is 
directly cardiotoxic and is known to cause myocarditis and dilated cardiomyopathy in children. [18,19] 
Children with cardiomyopathy are therefore likely to be at greater risk of acquiring severe pneumonia 
with or without further myocardial impairment secondary to the direct effects of adenovirus infection 
on the myocardium. 
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HIV infection in a South African context has been associated with severe pneumonia but in contrast to 
other pneumonia studies, the HIV prevalence in this study was relatively low {7%). HIV was not found to 
be associated with poor outcome in this study. Explanations for this observation include improved 
access to effective perinatal mother to child transmission (PMTCT) programmes which have reduced the 
rate of perinatal HIV infections in South Africa. [19] Furthermore, early initiation of antiretroviral 
treatment in HIV infected children is now the standard of care in South Africa. [20 ]. That said, severe 
pneumonia is common in HIV infected children and adenovirus should be considered in the aetiologicai" 
diagnosis along with other viruses and opportunistic infections such as Pneumocystis jeroveci and 
cytomegalovirus ( CMV). 1211 Positive bloodstream infection was associated with increased mortality in 
this study. The synergistic effect produced by bacterial and viral coinfection resulting in more severe 
illness than either factor independently has been documented. The primary viral infection alters the 
respiratory mucosa predisposing it to colonisation by secondary bacteria which alters the immune 
responses resulting in severe secondary bacterial infection. [•] 
The severity of AVP as measured by hypoxia and need for ICU admission was associated with 
development of both CLD and death. This finding was not unique to this study and is consistent with 
previous studies looking at outcomes following adenoviral infections [4,6,12,13,14,15]ln their 2006 study 
reviewing risk factors for BO following acute bronchiolitis, Celom et.al showed that adenoviral infection 
and mechanical ventilation were both risk factors for developing BO, a common chronic sequelae 
following adenovirus pneumonia. [15]Castro Rodriguez compared 38 patients with AVP who developed 
BO to those who did not develop BO in a five year follow up period and reported that mechanical 
ventilation, prolonged requirement of oxygen, more severe respiratory compromise and 
extrapulmonary manifestations of adenovirus infection with prolonged hospitalisation were risk factors 
for the development of BO which occurred in 47,4% of cases. [12] A study by Murtagh et.al from 
Argentina m 2009 identified mechanical ventilation as a risk factor for death but not for the 
development of BO. In their study of 415 children hospitalised with AVP, 49% recovered, 36% had 
chronic sequelae and 15% died.[•]ln our study over a one year period, 14% developed CLD and 9% died. 
The lower incidence of CLD and death in our cohort compared to the Argentinian study could be 
explained by different study design, different definition of CLD or different epidemiology of adenovirus 
serotypes and disease spectrum in our setting. 
This study has several limitations. First, the retrospective search for eligible patients may not have 
represented all the AVP cases as testing for respiratory viruses was not routinely performed on all 
children admitted with pneumonia. Bias toward more severe pneumonia cases may be present in this 
study as clinicians were likely to request viral testing when pneumonia was more severe. Secondly, we 
could not diagnose BO by standard high resolution computed tomography (HRCT) criteria as HRCT is not 
routinely performed in our setting in children recovering from severe pneumonia due to resource 
constraints and to limitation of unnecessary radiation exposure in children. We elected to categorise 
children with CLD if they remained oxygen dependent after 30 days of hospitalisation as this approach 
would capture the majority of children who would develop BO. Lastly, we were unable to identify 
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adenovirus serotypes in this study as testing for serotypes is not routinely offered in our setting. 
Knowledge of serotype patterns may explain some observed differences in the spectrum of AVP disease 
severity as described elsewhere. [23] 
In conclusion, AVP is an important cause of pneumonia and CLD in young children in South Africa. Severe 
AVP needing ICU admission and blood stream infection is associated with poor outcome. Early 
recognition of severe AVP is important to identify children at risk of developing chronic lung disease. 
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Table 1: Demographic, clinical and co-infection data in children with adenovirus-associated pneumonia, 
Januarv 2011-December 2011 (n-206) 
DEMOGRAPHIC DATA n=206 % 
Age(monthsl median IQR 12 (6-24) 
Male (n, %1 116 56% 
Female (n,% I 90 44% 
WAZ (mean,SD) 1,38 (1,91) 
WAZ<-2 (n/N, %1 70 34% 
Community Acquired (n/N, %) 148 72% 
Hospital Acquired (n/N ,% I 58 28% 
CLINICAL FEATURES 
Rash 5 2% 
Conjunctivitis 34 17% 
Fever more than 38 degree Celsius 159 77% 
Diarrhoea 31 15% 
UNDERLYING CONDITIONS 
Cardiac 48 23% 
Respiratory 26 13% 
Neurologic 15 7% 
Renal 4 2% --
Immune suppression 19 9% --
Prematurity 36 18% 
Other( including tracheostomy) 27 13% 
HIVSTATUS 
HIV exposed, uninfected 42 20% 
H IV infected 14 7% 
CD4% (median, IQRI n=14 18,1 (8-20.3) 
HIV viral load (log x10 61 (median IQR) 6,4 (5.1-6.61 
COINFECTIONS 
Viral, TB &positive blood culture 65 32% 
Rhinovirus 29 14% 
Parainfluenza virus 6 3% 
Influenza virus 8 4% 
Tuberculosis 11 5% 
Bloodstream infections 11 5% 
WAZ: weight-for-age z-score. 
HIV: Human immunodeficiency virus 
Table 2: Clinical factors associated with in-hospital mortality in children with adenovirus-associated 
pneumonia 
DIED ALIVE p-value 
Age (median, IQR) 19 (10-36) 2 (6-24) P~0,06 
WAZ. <-2 7/15 (47%) 63/77 (36%) P~0,7 --
Cardiac 8/18 (44%) 40/188 (21%) P~0,02 
Respiratory 1/18 (5,6 %) 25/188 (13%) P~0,35 
Immune Suppression 2/18 (11%) 17/188 (9%) P-0,70 
Prematurity 3/18 (17%) 33/188 (17%) P~0,92 
HIV infected 2/18 (11%) 54/188 (29%) P~0,78 
Hypoxia 17/18 (94%) 129/188 (69%) P~0,02 
ICU admission 14/18 (78%) 62/188 (32%) P~0,01 
Bloodstream infection 4/18 (22%) 7/188 (41%) P~0,01 
WAZ: weight-for-age 
ICU: intensive care unit 
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Appendices: DATA COLLECTION SHEET 
INITIALS: FOLDER NUMBER: 
DOB: AGE: M/F: RACE 
DATE OF RCH ADMISSION: 
DATE OF POSITIVE ISOLATE: 
CUNICAL INFORMATION REGARDING ILLNESS 




TEMP>38*> 48HRS: Y/N 
DIARRHOEA : Y /N 
UNDERLYING CHRONIC ILLNESS: 1-CARDIAC, 2-RESP, 3-GIT, 4-RENAL,S-NEURO 6-
IMMUNOSUPPRESSED, 7-EXPREM,8-TRACHEOSTOMY,9-0THER 




Hb CRP PCT 









ICU ADMISSION: Y/N DURATION: 
VENTILATORY SUPPORT: Y/N 
1-CPAP, 2-IPPV, 3-HFOV 4-NP02 
OUTCOMES: 
02 DEPENDENT > 1 MONTH : Y/N 
DAYS IN HOSPITAL: 
DEATH: Y/N CAUSE OF DEATH: 
DISCHARGED: V/N 
FULL RECOVERY: Y/N 
CHRONIC LUNG DISEASE: Y/N 
02 DEPENDENT> 1 MONTH: V/N 
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